What are the treatment options for a 55-year-old female with symptoms of high Dehydroepiandrosterone (DHEA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Symptoms and Treatment of Elevated DHEA in a 55-Year-Old Female

In a 55-year-old female with elevated DHEA, the primary concern is identifying an underlying adrenal androgen-secreting tumor, particularly adrenocortical carcinoma, which requires urgent imaging and endocrine evaluation. 1, 2

Clinical Manifestations of High DHEA

Elevated DHEA in postmenopausal women manifests through androgenic symptoms that reflect excessive androgen exposure:

Virilization Signs

  • Hirsutism (excessive facial and body hair growth) 1
  • Deepening of the voice 1
  • Androgenetic alopecia (male-pattern baldness) 2
  • Clitoral enlargement (clitoromegaly) 2
  • Oligomenorrhea or amenorrhea (though less relevant in a 55-year-old postmenopausal woman) 1

Dermatologic Manifestations

  • Acne (particularly severe or treatment-resistant) 1
  • Oily skin from increased sebum production 3

Metabolic Effects

  • Weight gain 1
  • Hypertension 1
  • Hyperglycemia 1

Diagnostic Approach

The critical first step is distinguishing between benign and malignant causes of DHEA elevation, as this fundamentally determines treatment strategy. 2

Initial Hormone Panel

  • Free and total testosterone 2
  • DHEA-sulfate (DHEAS) to confirm elevation 2
  • Cortisol levels (24-hour urine cortisol if Cushing syndrome suspected) 1
  • ACTH level to determine if hypercortisolism is ACTH-dependent 1
  • 17-hydroxyprogesterone to rule out non-classical congenital adrenal hyperplasia 2

Imaging Studies

Adrenal CT with contrast is mandatory when DHEA elevation suggests adrenal pathology. 1 Look for:

  • Tumor size >4 cm (highly suspicious for malignancy) 1
  • Irregular margins or heterogeneous appearance 1
  • Hounsfield units >10 on unenhanced CT (lipid-poor lesions suggest malignancy) 1
  • Poor contrast washout 1
  • Adjacent lymph node involvement or liver metastases 1

Treatment Based on Etiology

Adrenocortical Carcinoma (Malignant)

If imaging reveals features suspicious for adrenocortical carcinoma (size >5 cm, irregular margins, heterogeneous appearance), open adrenalectomy is the definitive treatment. 1

  • Avoid laparoscopic approach for suspected malignancy due to rupture risk 1
  • Complete staging with chest, abdomen, and pelvis imaging to evaluate for metastases 1
  • Postoperative corticosteroid supplementation is required until HPA axis recovery 1

Benign Adrenal Adenoma

For benign-appearing androgen-secreting adenomas, laparoscopic adrenalectomy is the treatment of choice when feasible. 1

  • Tumors <5 cm with homogeneous appearance and regular margins suggest benign pathology 1
  • Postoperative glucocorticoid replacement is necessary until the contralateral adrenal recovers 1

Medical Management for Palliation

When surgery is not feasible or for symptom control, medical management targets the androgenic manifestations. 1

Anti-Androgen Therapy

  • Spironolactone (50-200 mg daily) for hirsutism and acne 1
  • Combined oral contraceptives (though less applicable in a 55-year-old) 1
  • Finasteride (5 mg daily) for androgenic alopecia 1

Adrenostatic Agents (for unresectable tumors)

  • Ketoconazole (400-1200 mg/day) is most commonly used due to tolerability 1
  • Mitotane for adrenocortical carcinoma 1

Symptomatic Treatment

  • Antihypertensives for blood pressure control 1
  • Metformin for hyperglycemia and insulin resistance 1
  • Potassium supplementation if hypokalemia present 1

Critical Pitfalls to Avoid

Never dismiss elevated DHEA in a postmenopausal woman as benign without imaging, as approximately 60% of adrenocortical carcinomas present with hormone excess. 1

Do not perform laparoscopic adrenalectomy if malignancy is suspected, as these tumors are prone to rupture. 1

Do not delay endocrine consultation when DHEA elevation is confirmed, as timely diagnosis of adrenocortical carcinoma significantly impacts mortality. 1, 2

Monitor for signs of Cushing syndrome concurrently, as tumors secreting multiple hormones are more likely malignant. 1

Monitoring During Treatment

  • Serial imaging every 3-6 months if conservative management is chosen 1
  • Repeat hormone panels to assess treatment efficacy 2
  • Watch for progression of virilization as a marker of inadequate control 1
  • Assess for metabolic complications (diabetes, hypertension, osteoporosis) 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Elevated DHEA-Sulfate: Clinical Significance and Diagnostic Approach

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.

Proceedings of the National Academy of Sciences of the United States of America, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.